IBI305 vs Zirabev (bevacizumab-bvzr)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

IBI305

Marketed by Innovent Biologics

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02954172 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin.

Reported efficacy

Objective Response Rate (18 weeks): Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. (met)

Result source: NCT02954172

Zirabev (bevacizumab-bvzr)

Marketed by Pfizer

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02364999 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.

Reported efficacy

Objective Response Rate (ORR) by Week 19 (25 weeks): Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) (met)

Result source: NCT02364999

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIBI305Zirabev (bevacizumab-bvzr)
PFS, median8.4 vs 8.3vs Bevacizumabn 221NCT02954172—Not reported
OS, median18.0n 221NCT02954172—Not reported
ORR44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT0295417245.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999
Duration of response, median—Not reported8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999

PFS, median

IBI305
8.4 vs 8.3vs Bevacizumabn 221NCT02954172
Zirabev (bevacizumab-bvzr)
—Not reported

OS, median

IBI305
18.0n 221NCT02954172
Zirabev (bevacizumab-bvzr)
—Not reported

ORR

IBI305
44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172
Zirabev (bevacizumab-bvzr)
45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999

Duration of response, median

IBI305
—Not reported
Zirabev (bevacizumab-bvzr)
8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. IBI305: 3 of 4 rows · Zirabev (bevacizumab-bvzr): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIBI305Zirabev (bevacizumab-bvzr)
Dropout rate
1.3%a
NCT02954172 · Phase 3 · combination
46.1%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—a
NCT02954172 · Phase 3 · combination
—
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
33.5%a
NCT02954172 · Phase 3 · combination
22.8%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · combination
alopecia 46.6%
anaemia 28.7%
fatigue 20.5%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

IBI305

Overall Survival 18.02 vs NA Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination
PFS 8.43 vs 8.26 Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination

Zirabev (bevacizumab-bvzr)

Duration of Response 8.38 vs 6.62 Bevacizumab-EU months
time to event · months
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to months from 36.3 weeks as posted
PFS 32.3% (n=358) vs 30.5% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 65.8% (n=358) vs 64.1% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IBI305's landscape · Zirabev (bevacizumab-bvzr)'s landscape